We are intensely focused on developing bladder cancer therapeutics.

CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Learn about CG0070

Cretostimogene grenadenorepvec (CG0070) is a targeted oncolytic immunotherapy agent that has shown remarkable efficacy in bladder cancer.

Learn More

CG Oncology MOA

CG Oncology by the Numbers.

3

Active clinical programs
with planned studies soon underway. See current clinical trials.

88%

Complete response rate
at any time for CG0070 in combination with KEYTRUDA®

73%

Complete response rate
at 12 months for CG0070 in combination with KEYTRUDA®

Investors

acorn bioventures logo
ally bridge group logo
decheng capital logo
kissei pharmaceutical logo
lepu medical logo
longitude capital logo
malin corporation logo
ori capital logo
ra capital logo
sirona capital logo